OnCore Biopharma, Inc.
http://www.oncorebiopharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From OnCore Biopharma, Inc.
Generic Hetlioz Does Not Require Braille Labeling, FDA Tells Vanda
FDA says Teva and Apotex’s generic products do not violate the ‘same labeling’ requirement because they were produced by different manufacturers and that braille is not necessary for safe and effective use of tasimelteon products. Vanda's generic labeling suit against the FDA remains pending.
Generic Hetlioz Does Not Require Braille Labeling, FDA Tells Vanda
FDA says Teva and Apotex’s generic products do not violate the ‘same labeling’ requirement because they were produced by different manufacturers and that braille is not necessary for safe and effective use of tasimelteon products. Vanda's generic labeling suit against the FDA remains pending.
Moderna Again Faces Claims It Excluded Others’ Work In Developing COVID-19 Vaccine
Arbutus Biopharma alleges Moderna refused to license patents covering its lipid nanoparticle delivery platform in developing Spikevax. Moderna says it created its own proprietary LNP delivery technology.
Hep B Cure May Lie In Reducing Surface Antigen
Among the topics at the European liver meeting was whether reducing HBV surface antigen might be part of a combination approach to curing chronic hepatitis B. One of the leaders in this approach, Arbutus, is working toward its own internal combo therapy for the virus.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Enantigen Therapeutics, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice